Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Therapy of hepatitis C

M W Fried1, J H Hoofnagle

  • 1Division of Digestive Diseases, Emory University School of Medicine, Atlanta, Georgia, USA.

Seminars in Liver Disease
|February 1, 1995
PubMed
Summary
This summary is machine-generated.

Alpha interferon may reduce chronic hepatitis C by treating acute infections. For chronic cases, it offers temporary remission in 50% and sustained remission in 15-20% of patients.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Psychometric properties of the PROMIS short form measures in a U.S. cohort of 961 patients with chronic hepatitis C prescribed direct acting antiviral therapy.

Alimentary pharmacology & therapeutics·2018
Same author

Clinical and metabolic effects associated with weight changes and obeticholic acid in non-alcoholic steatohepatitis.

Alimentary pharmacology & therapeutics·2018
Same author

Ledipasvir-sofosbuvir and sofosbuvir plus ribavirin in patients with chronic hepatitis C and bleeding disorders.

Haemophilia : the official journal of the World Federation of Hemophilia·2017
Same author

Complications of percutaneous liver biopsy with Klatskin needles: a 36-year single-centre experience.

Alimentary pharmacology & therapeutics·2017
Same author

Determination of hepatitis B phenotype using biochemical and serological markers.

Journal of viral hepatitis·2016
Same author

Noninvasive markers for staging fibrosis in chronic delta hepatitis.

Alimentary pharmacology & therapeutics·2016

Area of Science:

  • Hepatology
  • Virology
  • Immunology

Background:

  • Hepatitis C virus (HCV) infection poses a significant public health challenge, with a high rate of progression to chronic disease.
  • The efficacy of alpha interferon in acute hepatitis C is not definitively established, but some studies suggest a potential benefit in reducing chronicity.

Purpose of the Study:

  • To evaluate the role of alpha interferon in treating acute and chronic hepatitis C.
  • To determine optimal treatment regimens and identify patient subgroups most likely to benefit from interferon therapy.

Main Methods:

  • Review of small trials investigating alpha interferon for acute hepatitis C.
  • Analysis of treatment outcomes for chronic hepatitis C patients receiving alpha interferon therapy.
  • Identification of factors influencing treatment response, including patient demographics and viral load.

Related Experiment Videos

Main Results:

  • Alpha interferon treatment (3 mu thrice weekly for 24 weeks) is suggested for acute hepatitis C if HCV RNA remains detectable for one month.
  • In chronic hepatitis C, 24-48 weeks of alpha interferon therapy yields temporary remission in 50% of patients, with sustained remission in 15-20%.
  • Younger patients with shorter disease duration, no cirrhosis, and lower HCV RNA levels show better response rates, though prediction remains challenging.

Conclusions:

  • Alpha interferon is a potential treatment for acute hepatitis C to prevent chronicity and remains the sole approved therapy for chronic hepatitis C.
  • Despite its limitations, including side effects and modest sustained remission rates, ongoing research aims to improve interferon efficacy and develop novel therapeutic agents.